Patents Assigned to China Medical University
  • Publication number: 20210386695
    Abstract: The present disclosure relates to a method for inhibiting a binding of a SARS-CoV-2 spike protein of a SARS-CoV-2 to an angiotensin-converting enzyme 2 including contacting the SARS-CoV-2 with a sufficient concentration of disulfiram, a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram, and a method for inhibiting an activity of a papain-like protease (PLpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram. A method for inhibiting a replication or an infection of a SARS-CoV-2 in a cell includes contacting the cell with a sufficient concentration of disulfiram and a medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of disulfiram are also provided.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 16, 2021
    Applicant: China Medical University
    Inventors: Chang-Hai Tsai, Mien-chie Hung, Yeh Chen, Wen-Hao Yang, Chia-shin Yang, Yu-Lin Hung, Yu-Chuan Wang, Yi-Zhen Chou, Mei-Hui Hou, Chia-Ling Tsai, Bao-Yue Huang, Chian-Fang Hung, Hsiao-Fan Chen, Wen-Chi Su, Wei-Jan Wang
  • Publication number: 20210388439
    Abstract: The invention relates to method of diagnosis a subject suffering from Adult-onset Still's disease and further to determine the disease course of the subject suffering from Adult-onset Still's disease.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 16, 2021
    Applicant: CHINA MEDICAL UNIVERSITY
    Inventors: Der-Yuan Chen, Chin-An Yang
  • Publication number: 20210341491
    Abstract: The present invention relates to a peptide capable of binding to rheumatoid arthritis autoantibodies, which is a consecutive 10-25 amino acid sequence of any one fragment of the group consisting of SEQ ID NO: 3-4, 7-13 or 16-19, wherein the peptide fragment has an epitope that binds to the rheumatoid arthritis autoantibodies. Furthermore, the peptide fragment bound to the rheumatoid arthritis autoantibodies is used for testing rheumatoid arthritis, and according to this use, the present invention provides a method for testing rheumatoid arthritis disease and a test reagent kit used for determining whether a subject to be tested suffers from rheumatoid arthritis disease.
    Type: Application
    Filed: January 20, 2020
    Publication date: November 4, 2021
    Applicant: China Medical University
    Inventors: Gregory Tsay, Hsin-Yi Peng
  • Patent number: 11164676
    Abstract: A computer-aided recognition system for treatment response of rectal cancer is provided to predict the probability of a pathological complete response (pCR) of a rectal cancer patient after preoperative neoadjuvant chemoradiotherapy. The system includes a random forest model having several decision trees. Each decision tree has at least a feature node. Each feature node generates two branches according to a feature threshold, wherein each branch connects to another feature node or corresponds to an elementary pCR predicting probability. The random forest model integrates the elementary pCR probability of each decision tree, so as to generate a final pCR probability.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 2, 2021
    Assignee: CHINA MEDICAL UNIVERSITY HOSPITAL
    Inventors: Chia-Hung Kao, Shang-Wen Chen, Wei-Chih Shen, Kuo-Chen Wu
  • Publication number: 20210330661
    Abstract: The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.
    Type: Application
    Filed: April 22, 2021
    Publication date: October 28, 2021
    Applicant: China Medical University
    Inventors: Mien-Chie Hung, Yeh Chen, Wen-Hao Yang, Chia-Shin Yang, Yu-Lin Hung, Yu-Quan Wang, Yi-Zhen Chou, Mei-Hui Hou, Chia-Ling Tsai, Bao-Yue Huang, Chian-Fang Hung
  • Publication number: 20210301318
    Abstract: The present invention relates to a biomarker and target for diagnosis, prognosis and treatment of ankylosing spondylitis (AS). The present invention also relates to a method for producing an animal model for AS, an animal model produced therefrom, and a method for screening for an agent pharmaceutically active in the treatment of A S using such animal model.
    Type: Application
    Filed: July 10, 2019
    Publication date: September 30, 2021
    Applicants: ACADEMIA SINICA, BUDDHIST TZU CHI MEDICAL FOUNDATION, CHINA MEDICAL UNIVERSITY
    Inventors: Kuo-I LIN, Shih-Chieh HUNG, Chin-Hsiu LIU
  • Publication number: 20210283087
    Abstract: The present invention provides a pharmaceutical composition for treating and/or relieving myopia, the pharmaceutical composition comprises a therapeutically effective amount of an anti-inflammatory agent and a pharmaceutically acceptable carrier; the pharmaceutical composition of the present invention is safe, and can treat and/or relieve myopia by the anti-inflammatory agent. The pharmaceutically acceptable carrier can effectively encapsulate the anti-inflammatory agent at a specific ratio, and the stability and solubility of the pharmaceutical composition can be enhanced.
    Type: Application
    Filed: March 24, 2020
    Publication date: September 16, 2021
    Applicants: China Medical University, Sundragon Biomedical Electronics Co., LTD.
    Inventors: Lei WAN, Hui-Ju LIN
  • Patent number: 11117888
    Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: September 14, 2021
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Ching-Shih Chen, Hsiang-Wen Lin, Chih-Shiang Chang, Po-Chen Chu
  • Patent number: 11110129
    Abstract: A method for treating a multiple sclerosis is provided. The method includes administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, in which each of the mesenchymal stem cells expresses insulin-like growth factor 1 receptors.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: September 7, 2021
    Assignee: China Medical University
    Inventors: Woei-Cherng Shyu, Chen-Huan Lin, Wei Lee, Chia-Hung Hsieh, Chung-Y Hsu, Chang-Hai Tsai
  • Publication number: 20210270835
    Abstract: Disclosed are a biomarker, method and assay kit for identifying and screening for urothelial carcinoma (UC) in a subject in need.
    Type: Application
    Filed: June 21, 2019
    Publication date: September 2, 2021
    Applicant: CHINA MEDICAL UNIVERSITY
    Inventors: Chao-Jung CHEN, Chiu-Ching HUANG
  • Publication number: 20210220094
    Abstract: A method of repairing an oral defect model includes performing a three-dimensional oral defect model obtaining step, a defect cutting line detecting step, a defect point selecting step and a smoothing step. The three-dimensional oral defect model obtaining step is performed to scan an oral cavity to obtain a three-dimensional oral defect model message. The defect cutting line detecting step is performed to detect a defect cutting line of the three-dimension oral defect model message, and drive a displayer to display the defect cutting line. The defect point selecting step is performed to select at least one defect feature point of the defect cutting line via the displayer. The smoothing step is performed to perform a smoothing process at the at least one defect feature point, and convert the three-dimensional oral defect model message into a three-dimensional oral repaired model message to smooth the defect cutting line.
    Type: Application
    Filed: January 12, 2021
    Publication date: July 22, 2021
    Applicant: China Medical University
    Inventors: Yen-Wen Shen, Lih-Jyh Fuh, Chi-Hsiung Yu
  • Publication number: 20210221801
    Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.
    Type: Application
    Filed: January 22, 2020
    Publication date: July 22, 2021
    Applicant: China Medical University
    Inventors: Ching-Shih Chen, Hsiang-Wen Lin, Chih-Shiang Chang, Po-Chen Chu
  • Patent number: 11066378
    Abstract: The present invention develops a series of methyl caffeate derivatives having biological activity in anti-angiogenesis. The present invention suggests that the compounds of the invention possess inhibiting angiogenesis through regulation of VEGF/VEGFR-2 and its downstream signaling cascades in the vascular endothelial cells (VECs).
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 20, 2021
    Assignees: Taipei Medical University, China Medical University
    Inventors: Chieh-Hsi Wu, Yueh-Hsiung Kuo, Chun-Hsu Pan
  • Patent number: 11062445
    Abstract: A method of medical image registration is to be implemented by a computer device, and includes steps of: obtaining an ultrasound target image corresponding to an area of interest in an ultrasound image; for each of multiple computed tomography (CT) images, obtaining a CT candidate image that corresponds to an area of interest in the CT image; for each of the CT candidate images, calculating a similarity between the CT candidate image and the ultrasound target image; making one of the CT candidate images that corresponds to the greatest similarity among the CT candidate images serve as a CT target image; and performing image registration on the ultrasound target image and the CT target image.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 13, 2021
    Assignees: HIWIN TECHNOLOGIES CORP., CHINA MEDICAL UNIVERSITY
    Inventors: Bao-Yu Hsieh, Tzung-Chi Huang, Hsien-Te Chen, You-Min Chen, Yi-Cheng Liu
  • Publication number: 20210208165
    Abstract: The present invention provides a biomarker, method and assay kit for identifying and screening nephropathy, particularly diabetic nephropathy, in a subject in need, or predicting diabetic nephropathy or early progressive renal function decline (ERFD) in a diabetic patient.
    Type: Application
    Filed: June 21, 2019
    Publication date: July 8, 2021
    Applicant: CHINA MEDICAL UNIVERSITY
    Inventors: Chao-Jung CHEN, Fuu-Jen TSAI
  • Patent number: 11049276
    Abstract: A positioning guidance method for tooth brackets is provided. The positioning guidance method includes: obtaining, via an image capturing unit, an oral image; obtaining, via a processor, a position of a candidate tooth according to the contour of a plurality of teeth in the oral image; obtaining, via the processor, a bracket setting position corresponding to the candidate tooth by accessing dental model information from a storage device according to the position of the candidate tooth; obtaining, via the processor, a bracket image corresponding to a bracket from the oral image; and displaying, via the processor, guidance indication on a display unit according to a bracket position corresponding to the bracket image and the bracket setting position.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: June 29, 2021
    Assignees: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE, CHINA MEDICAL UNIVERSITY
    Inventors: Jian-Ren Chen, Guan-An Chen, Su-Chen Huang, Yin-Chun Liu, Yue-Min Jiang, Chien-Hung Yu, Yu-Cheng Lo
  • Patent number: 11040055
    Abstract: Methods and compositions for treating diabetic retinopathy employ an ophthalmic, topical formulation of micro-RNA 195 packaged in or on a nanoparticle or vesicle.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 22, 2021
    Assignee: China Medical University
    Inventors: Suh-Hang Hank Juo, Chung-Ling Liang, Tzu-Ming Wang
  • Publication number: 20210142477
    Abstract: The present disclosure provides a bone age assessment and height prediction system including an image capturing unit and a non-transitory machine readable medium. The image capturing unit is for obtaining a target x-ray image data of a subject. The non-transitory machine-readable medium is for storing a program for assessing the development of the bones of a hand and the bone age of the subject, and predicting the adult height of the subject when executed by a processing unit. Therefore, the bone age assessment and height prediction system of the present disclosure can effectively improve the accuracy and sensitivity of the bone age assessment and the height prediction, and the time for assessing the bone age and predicting the height can be further shorten.
    Type: Application
    Filed: August 1, 2018
    Publication date: May 13, 2021
    Applicant: China Medical University Hospital
    Inventors: Fuu-Jen Tsai, Tzung-Chi Huang, Ken Ying-Kai Liao, Jiaxin Yu
  • Publication number: 20210122825
    Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 2, 2020
    Publication date: April 29, 2021
    Applicant: China Medical University Hospital
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Chia-Ing Jan, Chih-Ming Pan, Shi-Wei Huang
  • Patent number: 10988733
    Abstract: A method for obtaining a plurality of pluripotent adult olfactory stem cells (APOSCs) includes isolating the APOSCs, culturing the isolated APOSCs in a sphere culture medium, and collecting the cultured APOSCs that express Bmi-1 (B-lymphoma moloney murine leukemia virus insertion region-1), Oct-4 (Octamer-binding transcription factor 4), Sox-2 (Sex-determining region Y (SRY)-box 2), Nanog, SSEA-4 (Stage-specific embryonic antigen-4), ki67, c-Myc, KLF-4 (Kruppel Like Factor 4), K14 (Cytokeratin 14) and ICAM-1 (Intercellular Adhesion Molecule 1).
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: April 27, 2021
    Assignee: China Medical University
    Inventors: Woei-Cherng Shyu, Chung-Y. Hsu, Der-Yang Cho, Chen-Huan Lin, Wei Lee, San-Yuan Chen, Long-Bin Jeng, Chang-Hai Tsai